Other

THE NEW ENGLAND JOURNAL OF MEDICINE                                                                                 Dec. 3, 2014
By Edward Cox, M.D., M.P.H., Luciana Borio, M.D., and Robert Temple, M.D.

...Studying investigational therapies for EVD presents scientific, practical, and ethical challenges. Not surprisingly, there has been substantial debate about the best and most appropriate study approaches.2,3 It is generally agreed that a trial with a concurrent control group, in which patients are randomly assigned to receive the test drug plus the best available supportive care (BASC) or to BASC alone, would be the most efficient and reliable way to evaluate the safety and effectiveness of candidate products.

 Some people in the health care community, however, have argued against such trials, urging instead use of a historical control — that is, making investigational drugs as widely available as their supply allows and then comparing mortality rates among treated patients with rates that would have been expected absent the drugs, on the basis of past experience with EVD.

French President Francois Hollande is to arrive in Guinea, becoming the first Western leader to visit a nation hit hard by the deadly Ebola virus.

He will deliver "a message of solidarity" to Guinea, where more than 1,200 have died of Ebola.

Meanwhile Guinea is to trial a new Ebola test that will deliver results six times faster than current methods.

The outbreak was now "stable" in the West African country, the World Health Organization (WHO) said last week.

France has pledged 100m euros (£79m; $125m) to help tackle the disease by opening several care centres in Guinea, a former French colony.

Read complete story
http://www.bbc.com/news/world-africa-30241374

CENTER FOR INFECTIOUS DISEASE RESEARCH AND POLICY
By Lisa Schnirring                                               Nov.18, 2014

Quicker and simpler diagnostic tests for Ebola could go a long way in helping break chains of disease transmission in West Africa's outbreak region, the World Health Organization (WHO) said today, as it unveiled two new initiatives to expedite their development.

The WHO said it hopes new efforts—similar to those under way to test and deliver an Ebola vaccine—can compress the development of a rapid test in months instead of years.

Standard reverse-transcriptase polymerase chain reaction (RT-PCR) tests used in mobile and other labs in the outbreak are very accurate when conducted by trained staff, but they require a full tube of blood, take 2 to 6 hours to get a result, and costs around $100 per test, the WHO said today in a statement....

NEW YORK TIMES                                                                                         Nov. 16, 2014

EDITORIAL

Recent gains in controlling the Ebola epidemic in West Africa have been encouraging, but they offer no reason for complacency. In Liberia, the hardest-hit country, the rate of new infections has declined in some areas, and several treatment units have been reporting empty beds for more than a month. But in adjacent Sierra Leone the number of new cases has shot upward, while in Guinea, where the epidemic started, the incidence of new cases appears to have stabilized over all, with growth in some districts and declines in others. All told, Ebola has infected more than 14,000 people in West Africa and killed more than 5,000 of them...